CymaBay Therapeutics Current Ratio 2013-2019 | CBAY

CymaBay Therapeutics current ratio from 2013 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
CymaBay Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-03-31 $0.27B $0.01B 18.66
2018-12-31 $0.18B $0.01B 12.60
2018-09-30 $0.20B $0.01B 14.83
2018-06-30 $0.22B $0.02B 12.81
2018-03-31 $0.23B $0.02B 12.90
2017-12-31 $0.10B $0.02B 6.35
2017-09-30 $0.10B $0.01B 7.39
2017-06-30 $0.02B $0.01B 1.49
2017-03-31 $0.03B $0.01B 2.28
2016-12-31 $0.02B $0.01B 1.99
2016-09-30 $0.02B $0.01B 3.16
2016-06-30 $0.03B $0.01B 4.00
2016-03-31 $0.04B $0.01B 5.41
2015-12-31 $0.04B $0.01B 6.88
2015-09-30 $0.05B $0.01B 7.89
2015-06-30 $0.03B $0.01B 3.31
2015-03-31 $0.03B $0.01B 2.52
2014-12-31 $0.04B $0.02B 1.82
2014-09-30 $0.04B $0.02B 2.95
2014-06-30 $0.03B $0.01B 1.85
2014-03-31 $0.03B $0.02B 1.99
2013-12-31 $0.03B $0.01B 3.40
2013-09-30 $0.03B $0.00B 14.32
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-12-31 $0.00B 0.00
2012-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.427B $0.010B
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $53.484B 9.74
Mylan (MYL) United Kingdom $9.330B 4.08
Bausch Health Cos (BHC) Canada $8.157B 5.57
Teva Pharmaceutical Industries (TEVA) Israel $8.044B 3.15
Dr Reddy's Laboratories (RDY) India $6.263B 23.43
ASPEN PHARMACR (APNHY) South Africa $3.213B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.677B 16.76
Amphastar Pharmaceuticals (AMPH) United States $0.912B 51.00
Homology Medicines (FIXX) United States $0.907B 0.00
Voyager Therapeutics (VYGR) United States $0.896B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.580B 0.87
Akorn (AKRX) United States $0.483B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.446B 0.00
Assembly Biosciences (ASMB) United States $0.332B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.228B 0.00
Sol-Gel Technologies (SLGL) Israel $0.185B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.165B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.057B 0.00